[go: up one dir, main page]

WO1993010236A1 - Allergenes proteiques de l'espece cynodon dactylon - Google Patents

Allergenes proteiques de l'espece cynodon dactylon Download PDF

Info

Publication number
WO1993010236A1
WO1993010236A1 PCT/AU1992/000615 AU9200615W WO9310236A1 WO 1993010236 A1 WO1993010236 A1 WO 1993010236A1 AU 9200615 W AU9200615 W AU 9200615W WO 9310236 A1 WO9310236 A1 WO 9310236A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid sequence
nucleic acid
cyn
clone
nucleotides
Prior art date
Application number
PCT/AU1992/000615
Other languages
English (en)
Inventor
Robert Bruce Knox
Mohan Bir Singh
Penelope Mary Smith
Original Assignee
The University Of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/969,875 external-priority patent/US6441157B1/en
Application filed by The University Of Melbourne filed Critical The University Of Melbourne
Priority to EP92923433A priority Critical patent/EP0668915A1/fr
Priority to JP50882993A priority patent/JP3618342B2/ja
Publication of WO1993010236A1 publication Critical patent/WO1993010236A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • I 5 Bermuda grass (Cynodon dactylon) is an important source of pollen allergens in many areas of the world, especially in tropical and sub-tropical climates. These allergens have been studied by a number of means including IgE imraunoblotting (Ford D., and Baldo, B.A. J. Allergy Clin. Immunol. 79: 711-720 (1987); Shen H.D., et al., Clin, Allergy 18: 401-409 (1988), column
  • the major allergen of Bermuda grass pollen allergen has been identified as a protein with a molecular weight (MW) in the range of 30-34 kD, binding IgE
  • Cyn d I (Kahn and Marsh, (1986) Mol. Immunol, 23:1281-1288; Marsh et al., (1988) Ann. Allergy, 60:499-504, Matthiesen et al, 1988, Supra).
  • Cyn d l is a. member of the Group I family of allergens (Kahn and Marsh, (1986) Supra, found in
  • Cyn d I differs from the Group I homologues of closely related grasses (Matthiesen and Lowenstein, (1991) Supra. The sequence of the first 27 amino acids at the N- terminus of Cyn dl has been determined.
  • Consequendy crude extracts are frequently used at high concentrations and may trigger potentially lethal systemic reactions, including anaphylaxis.
  • the product expressed from the cloned gene, fragments thereof, or synthetic peptides based on the sequence of the allergens provide a safer medium for therapy since they can be quality controlled, characterized and standardized, and they optimally do not bind IgE.
  • the present invention provides nucleic acid sequences coding for the major protein allergen of the species Cynodon dactylon (Cyn d I), or at least one fragment thereof or the functional equivalent of such nucleic acid sequences.
  • the present invention also provides expression vectors comprising such nucleic acid sequences and host cells transformed therewith.
  • the present invention further provides isolated recombinantly, chemically or synthetically produced Cyn d I or fragments thereof. Isolated Cyn d I or antigenic fragments thereof are useful for diagnosing and treating sensitivity in an individual to Bermuda grass pollen allergens.
  • Fig. 1 shows the nucleotide sequence coding for and deduced partial amino acid sequence of Cyn dl derived from a cDNA clone designated clone 2 (C2).
  • Fig. 2 shows a partial nucleotide sequence coding for and deduced partial amino acid sequence of Cyn d l, derived from a cDNA clone designated clone 18 (C18).
  • Fig. 3 shows a comparison of the nucleic acid sequences of clones 2 and 18.
  • Fig. 4 shows a comparison of the deduced amino acid sequences of clones 2 and 18.
  • Fig. 5 shows a comparison of the deduced amino acid sequences of 7 clones coding for Cyn d I; clone 18, (C18), clone 22 (C22), clone 23 (C23) clone 2 (C2), clone 3 (C3), clone 21 (C21), and clone 33 (C33);
  • Fig. 6 shows a partial nucleotide sequence coding for and deduced partial amino acid sequence of Cyn dl derived from a cDNA clone designated clone 14al.
  • SUBSTITUTE SHEET Fig. 7 shows the partial nucleotide sequence coding for partial and deduced partial amino acid sequence of Cyn dl derived from a cDNA clone designated clone 14cl.
  • Fig. 8 shows a partial amino acid sequence of Cyn dl designated Cyn d 1.14 predicted from a composite of clones 14al and 14cl.
  • Fig. 9 shows a predicted full-length amino acid sequence of Cyn d I designated Cyn d 1.18.
  • Fig. 10 shows a predicted partial amino acid sequence of Cyn dl designated Cyn d 1.2/3.
  • Fig. 11a shows separation by SDS-PAGE of protein fractions obtained by the primary preparative isoelectric focusing (IEF) of these proteins on the Rotofor.
  • Fig. lib shows a Western blot of separated proteins screened with MAb3.2.
  • Fig. 12a shows a separation by SDS-PAGE of protein fractions obtained by refractionation on the Rotofor of pooled fractions, 10-13, from a primary separation of crude pollen extract.
  • Fig. 12b shows separation by SDS-PAGE of protein fractions obtained by refractionation on the Rotofor of pooled fractions, 15-20, from a primary separation of crude pollen extract.
  • Fig. 13 shows Western blots of native Cyn d la and Cyn d lb separated by SDS-PAGE and probed with IgE from sera of individuals allergic to Bermuda grass.
  • Fig. 14 shows binding of MAbs 1D1, 3A2, 3C2 and 4D2 to cDNA clones from a Cyn dl ⁇ gtll librar .
  • the number on the overlay corresponds to the cDNA clone number.
  • SUBSTITUTE SHEET Fig. 15 shows a partial nucleotide sequence coding for and deduced partial amino acid sequence of Cyn d I derived from a cDNA clone designated clone 3.
  • Fig. 16 shows a partial nucleotide sequence coding for and deduced partial amino acid sequence of Cyn d I derived from a cDNA clone designated clone 22.
  • Fig. 17 shows a partial nucleotide sequence coding for and deduced partial amino acid sequence of Cyn d I derived from a cDNA clone designated clone 23.
  • Fig. 18 shows a nucleotide sequence and deduced amino acid sequence of Cyn d l derived from a full-length cDNA clone designated CD1.
  • Fig. 19 shows a partial nucleotide and deduced amino acid sequence of Cyn d I derived from a cDNA clone designated KAT-39-1.
  • Fig. 20 shows the comparison of predicted full-length amino acid sequences of the Cyn dl mature proteins designated Cyn dl. ⁇ >, Cyn d l.CDl and Cyn d l.2/3 (full-length).
  • the present invention provides nucleic acid sequences, or the functional equivalents thereof, coding for Cyn d I, the major allergen found in Bermuda grass pollen.
  • Cyn d I appears to be a family of closely related allergens.
  • a "family of allergens" are proteins related in function and amino acid sequence but encoded by genes at separate genetic loci. Each family member can have polymorphism in which nucleotide variation may occur at a given genetic loci. Polymorphism in the nucleic acid sequence may result in amino acid polymorphism, but this is not always the case as the nucleotide code which encodes for the amino acids is degenerate.
  • the nucleic acid sequence coding for Cyn dl may vary among individual Bermuda grass plants due to
  • a partial nucleic acid sequence coding for Cyn d I derived from a cDNA clone designated clone 2, has the sequence shown in Fig. 1.
  • the partial nucleic acid sequence coding for Cyn d I shown in Fig. 1 comprises 435 bases. The 3' untranslated region starts at base 436 and extends to base 662.
  • the deduced partial amino acid sequence of Cyn d I encoded for by clone 2 (C2) is also shown in Fig. 1.
  • Fig.2 shows the partial nucleic acid and deduced amino acid sequences for a second cDNA clone designated clone 18 (C18).
  • the nucleic acid sequence coding for Cyn d I shown in Fig. 2 comprises 600 nucleotides encoding 200 deduced amino acids.
  • the 3' untranslated region starts at base 601 and extends to base 775.
  • clones 2 and 18 may encode separate members of a Cyn d I gene family.
  • the deduced amino acid sequences encoded by clone 2 and clone 18 have 88.2% homology (84.1% identity). There are 22 amino acid differences in the 143 amino acid overlap deduced from the two clones of which 6 are conservative substitutions and 16 are non-conservative substitutions.
  • the partial protein encoded by clone 18 is two amino acids longer at the carboxy terminus than the partial protein encoded by clone 2 (Fig.4). Amino acid homology was demonstrated using software contained in PCGENE (Intelligenetics, Mountain View, CA).
  • FIG. 5 A comparison of the deduced amino acid sequences encoded by seven cDNA clones derived from the Cyn d 1 library as described in Example 1 are shown in Fig. 5.
  • the amino acid sequences encoded by these cDNA clones designated C2, C3, C21, C22, C23 and C33 are shown aligned with the deduced amino acid sequence encoded by clone 18 (C18), which is the longest clone derived from the Cyn d I cDNA library.
  • C18 the deduced amino acid sequence encoded by clone 18
  • Fig. 5 and Fig. 6 the overlapping portion of the amino acid sequences encoded by clones 18, 22, 23, 21 and 33 are identical. This suggests that clones 18, 22, 23, 21 and 33 are examples of the same Cyn d I gene family member.
  • clones 22 and 23 are two amino acids shorter than clone 18 and have different 3' untranslated regions (Figs. 2, 16 and 17). This may suggest that clones 22 and 23 represent a separate member of the Cyn d I gene family. Alternatively, they could represent differentially spliced forms of the same family member.
  • clones 2 and 3 may represent polymorphisms of a Cyn d I gene family member, which Cyn d I gene family member is different from the Cyn d I gene family member(s) to which clones 18, 21, and 33 belong.
  • a predicted partial amino acid sequence of Cyn d I designated Cyn d 1.2/3 as shown in Fig. 10 may be generated from the amino acid sequences encoded by clones 2 and 3.
  • Fig.6 shows the nucleotide sequence of cDNA clone 14al and its deduced amino acid sequence.
  • This clone was isolated from a PCR as described in Example 2 and the amino acid sequence it encodes corresponds to the amino portion of the Cyn d I family member partially encoded by clone 18. There is a 19 nucleotide overlap between the 3' end of clone Hal and the 5' end of clone 18.
  • Clone 14al was amplified in the PCR using oligonucleotide primers based on non-coding strand sequence of clone 18, as described in Example 2.
  • the methionine encoded by nucleotides 41-43 of clone I4al presumably represents the first amino acid of the translated protein.
  • Fig.7 shows the nucleotide sequence of cDNA clone 14c I and its deduced amino acid sequence.
  • This clone was also isolated from a PCR as described in Example 2 and the amino acid sequence it encodes corresponds to the amino portion of the Cyn d I family member partially encoded by clone 18.
  • This clone is homologous with clone 14al, but has one amino acid difference with clone I4al in the sequence of the mature protein (the N-terminus of the mature Cyn d I protein being indicated by amino acid I in Fig.7).
  • Clone 14c 1 has nucleotide differences in the leader sequence encoding seven amino acid differences with clone 14al, including a 12 nucleotide insert that would encode an additional 4 amino acids.
  • a composite sequence of 14al and 14c 1 including the potential polymorphisms of these clones is designated Cyn d 1.14 shown in Fig. 8.
  • the sequences of clones 14al and 14cl are useful in generating a predicted full-length nucleic acid sequence encoding Cyn d I.
  • Predicted full- length nucleotide sequences encoding Cyn d I may be derived from the formula:
  • L is a nucleic acid sequence of 0-300 nucleotides which includes nucleotides which encode a leader sequence of the Cyn d I protein and which may also include nucleotides of a 5' untranslated region
  • N is a nucleic acid sequence comprising up to 600 nucleotides and includes nucleotides which encode the amino terminus portion of mature Cyn d l
  • Y is that portion of the nucleic acid sequence of clone 2, clone 18, clone 3, clone 22, or clone 23 or any polymorphic form of those clones which encodes the mature Cyn d I protein
  • X is a nucleic acid sequence of 0-600 nucleotides which includes nucleotides of the 3' untranslated portion of Cyn d L
  • L ⁇ may include the nucleic acid sequence represented by nucleotides 1-106 of clone Hal as shown in Fig.
  • L ⁇ may also include the nucleic acid sequence represented by nucleotides 1-103 of clone 14cl as shown in Fig 7 which includes the 5' untranslated region of clone 14c 1 as well as those nucleotides (nucleotides 28-103 as shown in Fig. 7) of clone 14cl which encode a Cyn d I leader sequence.
  • L ⁇ may also be a nucleic acid sequence which includes nucleotides of clone Hal which encode only the leader sequence portion of Cyn d I
  • nucleotides 41-106 as shown in Fig. 6 or the nucleotides of clone 14 l which encode only the leader sequence portion of Cyn d I (nucleotides 28-103 as shown in Fig. 7) or any polymorphic form thereof.
  • L ⁇ is 0 and X is 0 and the formula then simply is NY.
  • N is preferably the nucleic acid sequence represented by encodes the full-length or mature Cyn d I protein.
  • a predicted full-length amino acid sequence for Cyn d I designated Cyn d 1.18 shown in Fig.9 can be generated by merging the amino acid sequence shown in Fig.8 designated Cyn d .14 with amino acid residues 53-246 of clone 18 as shown in Fig. 5.
  • the predicted composite of the mature protein in this case, which comprises amino acid 1-246 of Cyn d 1.18 shown in Fig. 9 would have a predicted molecular weight of approximately 26.7 kDa without any post- translational modifications.
  • the "mature" Cyn d I protein does not include the amino acid sequence of the leader portion of the Cyn d I protein.
  • polymorphism or potential polymorphism is shown in superscript and subscript
  • a full-length clone was generated using PCR as discussed in Example 3 and as shown in Figs. 18 and 20.
  • the full-length clone shown in Fig. 18 and designated clone CD1 was generated from a PCR using oligonucleotide primers based on nucleotides 107-125 of clone Hal (Fig 6) and nucleotides 604-621 of clone 18 (Fig. 2).
  • the deduced amino acid sequence of clone CD1 corresponds to the predicted composite full-length amino acid sequence of the Cyn d I protein family member designated Cyn d 1.18, as discussed above and as shown in Fig.9. with the exception of two amino acids.
  • Cyn d DL Cyn til.CDl is substantially the same Cyn d I protein as the predicted composite sequence represented by Cyn d 1.18 shown in Fig.9.
  • CD1 has been deposited with the ATCC under accession number .
  • Cyn d 1.2/3 Another predicted composite full-length amino acid sequence designated Cyn d 1.2/3 (full-length) is shown in Fig. 20. Part of this sequence is deduced from a Cyn d I clone which was generated from a PCR using oligonucleotide primers based on nucleotides 178-206 of clone 2 (Fig. 1) (which is identical to the corresponding nucleotide sequence of clone 3 (Fig. 15)) and nucleotides essentially identical to nucleotides 107-130 of clone Hal (Fig. 6). This clone was designated clone KAT- 39-1.
  • the nucleotide and deduced amino acid sequences of clone KAT-39-1 are shown in Fig 19.
  • the deduced amino acid sequence of clone KAT-39-1 represents a partial amino acid sequence of Cyn d I that overlaps with part of the predicted amino acid sequence of Cyn d 1.2/3 as shown in Fig. 10. Therefore, the composite sequence formed by combining the nucleic and deduced amino acid sequences of clone KAT-39-1 in conjunction with the nucleic and deduced amino acid sequences of Cyn d 1.2/3 represent the nucleic and deduced amino acid sequences of the predicted Cyn d I protein family member composite designated Cyn d 1.2/3 (full- length) as shown in Fig. 20.
  • Nucleic acids encoding Cyn d I protein allergens as described above may be obtained from any part of Cynodon dactylon plants.
  • Nucleic acids encoding Cyn d I may be obtained from genomic D A.
  • the nucleic acids coding for Cyn d I may be obtained using the methods disclosed herein or any other suitable technique for isolation and cloning of genes.
  • the foregoing fragments of Cyn rfl are referred to herein as antigenic fragments.
  • Fragments within the scope of the invention also include those capable of hybridizing with nucleic acid from other plant species for use in screening protocols to detect allergens that are cross-reactive with Cyn d I.
  • a fragment of the nucleic acid sequence coding for Cyn d I refers to a nucleotide sequence having fewer bases than the nucleotide sequence coding for the entire amino acid sequence of Cyn d I and/or mature Cyn d I.
  • nucleic acid sequence coding for the fragment or fragments of Cyn dl will be selected from the bases coding for the mature protein, however, in some instances it may be desirable to select all or a part of a fragment or fragments from the leader sequence portion of the nucleic acid sequence of the invention.
  • the nucleic acid sequence of the invention may also contain linker sequences, modified restriction endonuclease sites and other sequences useful for cloning, expression or purification of Cyn d I or fragments thereof.
  • the present invention provides expression vectors and host cells transformed to express the nucleic acid sequences of the invention.
  • Nucleic acid coding for Cyn d I, or at least one fragment thereof may be expressed in bacterial cells such as E. coll insect cells (baculov ⁇ rus), yeast, or mammalian cells such as Chinese hamster ovary cells (CHO).
  • bacterial cells such as E. coll insect cells (baculov ⁇ rus), yeast, or mammalian cells such as Chinese hamster ovary cells (CHO).
  • Suitable expression vectors, promoters, enhancers, and other expression control elements may be found in Sambrook et al. Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).
  • Other suitable expression vectors, promoters, enhancers, and other expression elements are known to those skilled in the art.
  • yeast or insect cells leads to partial or complete glycosylation of the recombinant material and formation of any inter- or intra-chain disulfide bonds.
  • Suitable vectors for expression in yeast include YepSecl (Baldari et al. (1987) Embo J. 6: 229-234); pMFa (Kurjan and Herskowitz (1982) Cell 30: 933-943); JRY88 (Schultz et al. (1987) Gene 54: 113-123) and pYES2 (Invitrogen Corporation, San Diego, CA). These vectors are freely available. Baculovirus and mammalian expression systems are also available.
  • a baculovirus system is commercially available (PharMingen, San Diego, C A) for expression in insect cells while the pMSG vector is commercially available (Pharmacia, Piscataway, NJ) for expression in mammalian cells.
  • suitable expression vectors include, among others, pTRC (Amann et al. (1988) Gene 69: 301-315); pGEX (Amrad Corp., Melbourne, Australia); pMAL (N.E. Biolabs, Beverly, MA); pRIT5 (Pharmacia, Piscataway, NJ); pET-lld (Novagen, Madison, WI) Jameel et al., (1990) J. Virol.
  • pMAL maltose E binding protein
  • pPJT5 protein A
  • PSEM truncated ⁇ -galactosidase
  • pGEX glutathione S-transferase
  • Cyn d I, fragment, or fragments thereof is expressed as a fusion protein
  • Cyn d l o ⁇ a fragment thereof may then be recovered from the fusion protein through enzymatic cleavage at the enzymatic site and biochemical purification using conventional techniques for purification of proteins and peptides.
  • Suitable enzymatic cleavage sites include those for blood clotting Factor Xa or thrombin for which the appropriate enzymes and protocols for cleavage are commercially available from, for example, Sigma Chemical Company, St. Louis, MO and N.E. Biolabs, Beverly, MA.
  • the different vectors also have different promoter regions allowing constitutive or inducible expression with, for example, IPTG induction (PRTC, Amann etal., (1988) supra; pET-lld, Novagen, Madison, WI) or temperature induction ( ⁇ RIT5, Pharmacia, Piscataway, NJ) . It may also be appropriate to express recombinant Cyn di m different E. coli hosts that have an altered capacity to degrade recombinantly expressed proteins (e.g. U.S. patent 4,758,512). Alternatively, it may be advantageous to alter the nucleic acid sequence to use codons preferentially utilized by E. coli, where such nucleic acid alteration would not affect the amino acid sequence of the expressed protein.
  • Host cells can be transformed to express the nucleic acid sequences of the invention using conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation. Suitable methods for transforming the host cells may be found in Sambrook et al. supra, and other laboratory textbooks.
  • the nucleic acid sequences of the invention may also be synthesized using standard techniques.
  • the present invention also provides a method of producing purified Cyn d I or at least one fragment thereof comprising the steps of culturing a host cell transformed with a DNA sequence encoding Cyn d I or at least one fragment thereof in an appropriate medium to produce a mixture of cells and medium containing Cyn d I or at least one fragment thereof; and purifying the mixture to produce substantially pure Cyn d I or at least one fragment thereof.
  • Host cells transformed with an expression vector containing DNA coding for Cyn d I or at least one fragment thereof are cultured in a suitable medium for the host cell.
  • Cyn d I protein and peptides can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and immunopurification with antibodies specific for Cyn d l or fragments thereof.
  • the terms isolated and purified are used interchangeably herein and refer to peptides, protein, protein fragments, and nucleic acid sequences substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when synthesized chemically. Accordingly, an isolated peptide of the invention is produced by recombinant D A techniques or synthesized chemically and is substantially free of cellular material, culture medium, chemical precursors or other chemicals.
  • Another aspect of the invention provides preparations comprising Cyn d I or at least one fragment thereof synthesized in a host cell transformed with a DNA sequence encoding all or a portion of Cyn d I, or chemically synthesized, and purified Cyn d I protein, or at least one antigenic fragment thereof produced in a host cell transformed with a nucleic acid sequence of the invention, or chemically synthesized.
  • the Cyn d I protein is produced in a host cell transformed with the nucleic acid sequence coding for at least the mature Cyn d I protein.
  • Fragments of Cyn d I can be obtained, for example, by screening peptides synthesized from the corresponding fragment of a nucleic acid sequence of the invention coding for such peptides or synthesized chemically using techniques known in the art
  • Peptide fragments of the allergen may be obtained by selection of fragments of a desired length with no overlap of the peptides, or selection of overlapping fragments of a desired length, which can be produced recombinantly or synthetically.
  • the fragments can be tested to determine antigenicity (e.g., the ability of the fragment to induce an immune response). Such fragments are referred to herein as antigenic fragments.
  • Fragments of Cyn d I protein allergen which are capable of eliciting a T cell response such as stimulation (i.e., proliferation or lymphokine secretion) and/or are capable of inducing T cell anergy are particularly desirable. Fragments of Cyn d I which do not bind immunoglobulin E (IgE) or bind IgE to a substantially lesser extent than the protein allergen from which the fragments are derived are also particularly desirable.
  • the major complications of standard immunotherapy are systemic responses such as anaphylaxis.
  • Immunoglobulin.E is a mediator of anaphylactic reactions which result from the binding and cross-linking of antigen to IgE on mast cells or basophils and the release of mediators (e.g., histamine, serotonin, eosinophil, chemotactic factors).
  • mediators e.g., histamine, serotonin, eosinophil, chemotactic factors.
  • anaphylaxis could be avoided by the use of a fragment which does not bind IgE, or if the fragment binds IgE, such binding does not result in the release of mediators (e.g., histamine ttc.) from mast cells or . basophils.
  • mediators e.g., histamine ttc.
  • fragments which have minimal IgE stimulating activity are particularly desirable for therapeutic effectiveness.
  • Minimal IgE stimulating activity refers to IgE stimulating activity which is less than the amount of IgE production stimulated by the whole Bermuda grass protein allergen.
  • Preferred fragments of the invention include but are not limited to fragments derived from amino acids 5-246, 10-246, 20-246 and 25-246 of Cyn d 1.18 as shown in Fig. 20; fragments derived from amino acids 5-246, 10-246, 20-246 and 25-246 of Cyn d LCD1 as shown in Fig.20; and fragments derived from amino acids 5-244, 10- 244, 20-244 and 25-244 of Cyn d 1.2/3 (full-length) as shown in Fig. 20.
  • Cyn tf I and preferred antigenic fragments thereof when administered to a Bermuda grass pollen-sensitive individual, are capable of modifying the allergic response of the individual to the allergen, and preferably are capable of modifying the B cell, the T cell response or both the B cell and the T cell response of the individual to the allergen.
  • modification of the allergic response of an individual sensitive to a Bermuda grass pollen allergen such as Cyn d I can be defined as non-responsiveness or diminution in symptoms to the allergen, as determined by standard clinical procedures (See e.g., Varney et al., British Medical Journal 302: 265-269 ( 1990)) including dimunition in Bermuda grass pollen induced asthmatic symptoms.
  • a dimunition in symptoms includes any reduction in symptoms in the allergic response of an individual to the allergen following a treatment regimen with a protein or peptide of the invention.
  • This dimunition in symptoms may be determined subjectively (i.e., the patient feels more comfortable upon exposure to the allergen), or clinically, such as with a standard test.
  • Initial screening for IgE binding to Cyn dl ot fragments thereof may be performed by scratch tests or intradermal skin tests on laboratory animals or human volunteers, or in in vitro systems such as RAST (radioallergosorbent test), RAST inhibition, ELISA assay, radioimmunoassay (RIA), or histamine release.
  • Antigenic fragments of the present invention which have T cell stimulating activity, and comprise at least one T cell epitope are particularly desirable.
  • T cell epitopes are believed to be involved in initiation and perpetuation of the immune response to a protein allergen which is responsible for the clinical symptoms of allergy. These T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate HLA molecule on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulation. These events lead to T cell proliferation, lymphokine secretion, local inflammatory reactions, recruitment of additional immune cells to the site, and activation of the B cell cascade leading to production of antibodies. One isotype of these antibodies.
  • T cell epitope is the basic element or smallest unit of recognition by a T cell receptor, where the epitope comprises amino acids essential to receptor recognition and may be contiguous and/or non-contiguous in the amino acid sequence of the protein. Amino acid sequences which mimic those of the T cell epitopes and which modify die allergic response to protein allergens are within the scope of this invention.
  • Exposure of patients to Cyn I or to the antigenic fragments of the present invention which comprise at least one T cell epitope may tolerize or anergize appropriate T cell subpopulations such that they become unresponsive to the protein allergen and do not participate in stimulating an immune response upon such exposure.
  • administration of Cyn d I or an antigenic fragment of the present invention which comprises at least one T cell epitope may modify the lymphokine secretion profile as compared with exposure to the naturally-occurring protein allergen or portion thereof (e.g. result in a decrease of TJL-4 and or an increase in IL-2).
  • Cyn d I or such antigenic fragment may influence T cell subpopulations which normally participate in the response to the allergen such that these T cells are drawn away from the site(s) of normal exposure to the allergen (e.g., nasal mucosa, skin, and lung) towards the site(s) of therapeutic administration of the fragment.
  • This redistribution of T cell subpopulations may ameliorate or reduce the ability of an individual's immune system to stimulate the usual immune response at the site of normal exposure to the allergen, resulting in a dimunution in allergic symptoms.
  • Cyn d I and fragments or portions derived therefrom (peptides) can be used in methods of diagnosing, treating and preventing allergic reactions to Bermuda grass pollen.
  • the present invention provides therapeutic compositions comprising isolated Cyn d I or at least one fragment thereof and a pharmaceutically acceptable carrier or diluent.
  • Cyn d I or at least one fragment thereof is preferably produced in a cell transformed to express the protein allergen or the fragment thereof or is synthetically prepared.
  • Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known techniques. Cyn d I or a fragment thereof can be administered to an individual in combination with, for example, an appropriate diluent, a carrier and or an adjuvant
  • Pharmaceutically acceptable diluents include saline and aqueous buffer solutions.
  • Pharmaceutically acceptable carriers include polyethylene glycol (Wie et al. (1981) Int. Arch.
  • the therapeutic composition is preferably administered in non-immunogenic form, e.g., it does not contain adjuvant.
  • Such compositions will generally be administered by injection (subcutaneous, intravenous etc.), oral administration, inhalation, transdermal application or rectal administration.
  • the therapeutic compositions of the invention are administered to Bermuda grass pollen-sensitive individuals in a treatment regimen at dosages and for lengths of time effective to reduce sensitivity (i.e, reduce the allergic response) of the individual to Bermuda grass pollen.
  • Effective amounts of the therapeutic compositions will vary according to factors such as the degree of sensitivity of the individual to Bermuda grass pollen, the age, sex, and weight of the individual, and the ability of the Bermuda grass pollen allergen or fragment thereof to elicit an antigenic response in the individual.
  • cDNA coding for a Cyn d I (or the mRNA from which it was u-anscribed) or a portion thereof can be used to identify similar sequences in any variety or type of plant and thus, to identify or "pull out" sequences which have sufficient homology to hybridize to the cDNA of the protein allergen or mRNA or portion thereof.
  • cDNA of the present invention may hybridize to DNA from temperate grasses such as rye-grass, Kentucky Blue grass, Timothy • grass and orchard grass, and from other grasses such as Bahia grass and sorghum, under conditions of low stringency. Those sequences which have sufficient homology (generally greater than 40%) can be selected for further assessment using the method described herein. Alternatively, high stringency conditions can be used. In this manner, DNA of the present invention can be used to identify, in other types of plants, preferably related families, genera, or species, sequences encoding polypeptides having amino acid sequences similar to that of a Cyn d I, and thus to identify allergens in other species.
  • the present invention includes not only the Bermuda grass allergen Cyn d I, but also other allergens encoded by DNA which hybridizes to DNA of the present invention.
  • the invention further includes isolated protein allergens or fragments thereof, excluding those protein allergens or fragments from the genus Lolium, which are immunologically related to Cyn d I or fragments thereof, such as by antibody cross-reactivity ⁇ or other immunological assay wherein the protein allergens or fragments thereof are capable of binding to antibodies specific for Cyn d l o ⁇ fragments of the invention or by T cell cross-reactivity wherein the isolated allergenic proteins or fragments thereof are capable of stimulating T cells specific for the proteins and peptides of the invention.
  • the invention also includes protein allergens or fragments thereof which have greater than 73% homology with Cyn d I or have greater than 90% homology with Cyn d I.
  • Proteins or peptides encoded by the cDNA of the present invention can be used, for example as "purified" allergens. Such purified allergens are useful in the standardization of allergen extracts which are key reagents for the diagnosis and treatment of sensitivity to Bermuda grass pollen.
  • proteins or fragments thereof based on the nucleic acid sequences of Cyn d I anti-peptide antisera, polyclonal antibodies or monoclonal antibodies can be made using standard methods. These sera or polyclonal or monoclonal antibodies can be used to standardize allergen extracts and/or used in purification of native or recombinant protein allergens.
  • compositions and biological activity can be made and administered for therapeutic purposes (e.g. to modify the allergic response of a Bermuda grass pollen-sensitive individual.
  • Administration of such peptides or protein may, for example, modify B-cell response to Cyn dl, T cell response to Cyn d l a ⁇ both responses.
  • Isolated peptides can also be used to study the mechanism of immunotherapy of Bermuda grass pollen allergy and to design modified derivatives or analogues useful in immunotherapy.
  • Cyn d l o ⁇ fragments thereof of the invention for such purposes as increasing solubility, enhancing therapeutic or preventive efficacy, or stability (e.g., shelf life ex vivo, and resistance to proteolytic degradation in vivo).
  • Modified Cyn d l or a. modified fragment thereof can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion, or addition, to modify immunogenicity and/or reduce allergenicity, or to which a component has been added for the same purpose.
  • the amino acid residues essential to T cell epitope function can be determined using known techniques (e.g., substitution of each residue and determination of presence or absence of T cell reactivity).
  • Those residues shown to be essential can be modified (e.g., replaced by another amino acid whose presence is shown to enhance T cell reactivity), as can those which are not required for T cell reactivity (e.g., by being replaced by another amino acid whose incorporation enhances T cell reactivity but does not diminish binding to relevant MHC).
  • Cyn dl or a fragment thereof can also be modified to incorporate one or more polymorphisms in the amino acid sequence of the protein allergen resulting from natural allelic variation.
  • D-amino acids, non-natural amino acids or non-amino acid analogues can be substituted or added to produce a modified protein or fragment within the scope of this invention.
  • Cyn dl o ⁇ fragments thereof can be modified using the polyethylene glycol (PEG) method of A. Sehon and co-workers (Wie et al. supra) to produce a peptide conjugated with PEG. Modifications of Cyn d l or fragments thereof can also include reduction/ alkylation (Tarr in: Methods of Protein Microcharac-terization, JJE. Silver ed.
  • PEG polyethylene glycol
  • Site-directed mutagenesis of DNA encoding Cyn dl or fragment thereof can be used to modify the structure. Such methods may involve PCR (Ho et al., Gene 77:51-59 (1989)) or total synthesis of mutated genes (Hostomsky, Z., et al., Biochem. Biophys. Res. Comm 161:1056-1063 (1989)). To enhance bacterial expression, the aforementioned methods can be used in conjunction with other procedures to change the plant codons in DNA constructs encoding the peptides
  • Cyn d I peptides which, when administered to a Bermuda grass pollen sensitive individual in sufficient quantities, will modify the individual's allergic response to Bermuda grass pollen. This can be done, for example, by examining the structure of Cyn d I and producing peptides (via an expression system or synthetically) to be examined for their ability to influence B cell and or T cell responses in Bermuda grass pollen sensitive individuals and selecting appropriate B or T cell epitopes recognized by the cells. Protein, peptides or antibodies of the present invention can also be used for detecting and diagnosing sensitivity to Bermuda grass pollen allergens.
  • components e.g., antibodies, T cells, B cells
  • an agent or a drug capable of blocking or inhibiting the ability of Cyn d l lo induce an allergic reaction in Bermuda grass pollen sensitive individuals Such agents could be designed, for example, in such a manner that they would bind to relevant anti- Cyn d I-IgE's, thus preventing IgE-allergen binding and subsequent mast cell degranulation. Alternatively, such agents could bind to cellular components of the immune system, resulting in suppression or desensitization of the allergic response to Bermuda grass pollen.
  • a non-restrictive example of this is the use of appropriate B and T cell epitope peptides, or modifications thereof, based on the cDNA/protein structures of the present invention to suppress the allergic response to Bermuda grass pollen. This can be carried out by defining die structures of B and T cell epitope peptides which affect B and T cell function in in vitro studies with blood components from Bermuda grass pollen sensitive individuals.
  • the DNA used in any embodiment of this invention can be cDN A obtained as described herein, or alternatively, can be any oligodeoxynucleotide sequence having all or a portion of a sequence represented herein, or their functional equivalents. Such oligodeoxynucleotide sequences can be produced chemically or mechanically, using known techniques.
  • a functional equivalent of an oligonucleotide sequence is one which is capable of hybridizing to a complementary oligonucleotide to which the sequence (or corresponding sequence portions) thereof hybridizes, or the sequence (or corresponding sequence portion) complementary to the nucleic acid sequences, and/or which encodes a product (e.g., a polypeptide or peptide) having the same functional characteristics of the product encoded by the sequence (or corresponding sequence portion).
  • a functional equivalent must meet one or both criteria will depend on its use (e.g., if it is to be used only as an oligoprobe, it need meet only the first criterion and if it is to be used to produce Cyn d I, it need only meet the second criterion).
  • Bermuda grass pollen was purchased from Greer Laboratories, Lenoir, NC, USA. To prepare the pollen extract of soluble proteins which was loaded on the Rotofor, 5 grams of Bermuda grass pollen was extracted three times by shaking with 10ml of lOmM phosphate buffered saline (PBS) for one hour at 4 °C. After each extraction, the mixture was centrifuged (2500 rpm, 10 minutes) and the supernatant collected. After three extractions the supernatants were pooled and filtered through a 3mm Whatman filter.
  • PBS lOmM phosphate buffered saline
  • This MAb was raised against purified Lol p I but was found to be cross-reactive with Group I homologues from nine other grasses including Bermuda grass (Kahn and Marsh, 1986, Mol. Immunol, 23, 1281-1288). Fractions containing the proteins of interest were pooled and refractionated in the Rotofor using the same conditions as above except that samples were focussed for 2.5 hours. The pH of each fraction was determined.
  • Proteins were transferred to nitrocellulose (Schleicher and Schuell, 0.45 ⁇ m) according to Towbin et al. (1979); Proc. Natl Acad. Sci. U.S.A. , 76, 4350-4354; at 120 mA overnight at 4°C. After protein transfer, non-specific binding sites were blocked by incubation of the Western blots in powdered milk [10% in lOmM TBS Crris-buffered saline: I50mM NaCl lOmM Tris.HCl, pH 7.5)].
  • Cyn d lb was found in all fractions of Fig. 12b but dominated the protein profile of fractions 1-12 (Fig. 12b). These fractions had a pH of 7.4; an indication of the pi of Cyn Jib.
  • Cyn d I proteins Cyn d la and Cyn d lb, isolated, as described above, and electrotransfered onto polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA) using lOmM CAPS 10% methanol (pH 11.0) as the transfer buffer (Ward et al., 1990) (3 [cyclohex laminoH -propane • sulfonic acid), were d en visualized by staining with Coomassie Brilliant Blue R250, destained in methanol acetic acid water (50:10:40, v/v/v) and washed extensively with deionized water.
  • the NH2-terminal amino acid sequence of both Cyn d la and Cyn d lb proteins was determined as described by Ward et al. (1990); Cyn d I proteins, isolated by Rotofor, were also purified using reverse-phase
  • Cyn d I The two Cyn d I components show minor amino acid sequence variations in their NH2-terminal regions and there is homology between Cyn d I and Lolp I from ryegrass (Table 1). TABLE 1: NH 2 -terminal sequences of Cyn d I isoallergens and Lol p I.
  • Anti-Cyn d I MAbs were obtained by intraperitoneal immunization of a Balb/c mouse with 50 ⁇ g of Cyn d I (isolated on the Rotofor, Biorad, Richmond, CA). RIBI (RIBI Immunochem, Hamilton, MT, USA; was used as an adjuvant in the first of four immunizations. The remaining intraperitoneal immunizations were in saline. Fusion and growth of hybridomas was essentially as described by Harlow and Lane 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory. Single cell cloning was by limited dilution. Hybridomas producing anti-Cyn d I antibodies were identified using an ELISA assay.
  • ELISA plates were coated overnight with 60 ⁇ g of Bermuda grass pollen extract diluted in CAPS buffer (6.67 mM NaC0 35mM NaHCO 3 pH 9.6). The wells were then washed three times with TPBS (PBS containing 0.1% Tween 20) and blocked for 30 minutes with PBS containing 1% BSA (PBS/BSA). lOO ⁇ L of primary antibody was added to each well and incubated for 60 minutes, followed by washing (as above) and incubation in ⁇ -gal labelled anti-mouse Ig (1/250 dilution in PBS/BSA, 60 minutes).
  • Aft er wash i n g 200 ⁇ L o f th e fl uo re s ce n t s u b s tr a t e 4-methylumbelliferyl-B-D-galactoside (MUG) was added to each well and incubated at 37 °C for 30 minutes. The plates were then read on the fluoroCount 96 flurometer (Pharmacia).
  • Antibodies which were positive by this method were designated 3A2, 4D2, 1D1 and 3C2 and tested for binding to Cyn dl on a Western blot of Bermuda grass pollen proteins separated by SDS-PAGE.
  • Poly (A+) mRNA was isolated from Bermuda grass pollen purchased from Greer Laboratories, Lenoir, NC, USA essentially as described by Herrin and Michaels (1984).
  • cDNA was synthesized using the Pharmacia cDNA synthesis kit and cloned into the Eco R I site of the vector lambda-gt 11.
  • Recombinant proteins from phage plaques were transferred to nitrocellulose filters by overlaying the plated cDNA library with nitrocellulose filters impregnated with IPTG. These filters were then incubated in mixed anti-Cyn d I MAbs. Binding of MAbs to recombinant proteins was visualized as described above. Plaques producing proteins which bound to anti-Cyn dl MAbs were isolated and purified.
  • Clones 2, 3, 18, 21, 22, 23 and 33 were chosen for further study on the basis of their antibody affinity.
  • cDNA inserts from clones 2, 3, 18, 21, 22, 23 and 33 were isolated from the phage and subcloned into pGEM-4Z (Promega) or Bluescript (Stratagene) vectors. DNA sequence was determined by double stranded sequencing carried out by the chain termination method (Sanger et al., Proc. Nat'lAcad. Sc , (1977), 74:5460-5463) using T7 polymerase (Pharmacia). The nucleotide and deduced amino acid sequences of these clones are shown in Fig. 1 (clone 2), Fig.2 (clone 18), Fig. 15 (clone 3), Fig. 16 (clone 22) and Fig. 17 (clone 23).
  • All clones sequenced show homology with each other, particularly in the open reading frame (ORF).
  • ORF open reading frame
  • nucleotide sequence homology between all clones sequenced and Lol p i, a major allergen of ryegrass.
  • the sequenced clones can be separated into three groups on the basis of nucleotide and deduced amino acid sequence homology, those with sequence most similar to clone 2 (i.e., clone 3), those with sequence most similar to clone 18 (i.e., clones 21 and 33), and those most similar to clone 22 (i.e., clone 23).
  • the deduced amino acid sequences encoded by the ORFs of clones 18 and 2 were compared to the deduced amino acid sequence of Lol p i (Perez et al, 1991 supra; Griffith et al, 1991, supra) JRg. 6). There is 67% amino acid homology between Lolp I and clone 18 and 72% between Lolp I and clone 2. The deduced amino acid sequences of clones 2 and 18 have 83% identity (87% homology) with each other. 3
  • Double-stranded cDNA was synthesized from approximately 4 ⁇ g of pollen RNA (Greer Labs, Lenoir, NC, USA) using the cDNA Synthesis System Plus kit (BRL, Bethesda, MD, USA). After a phenol extraction and ethanol precipitation, the cDNA was blunted with T4 DNA polymerase (Promega, Madison, WI, USA), and ligated to ethanol precipitated, self-annealed, AT, 5'- GGGTCTAGAGGTACCGTCCGATC-GATCATT-3', and AL, 5'-p- AATGATCGATGCT-3", oligonucleotides for use in a modified Anchored PCR (Marsh et al, 1986: Roux and Dhanarajan, 1990; Rafnar et al, 1991) reaction.
  • T4 DNA polymerase Promega, Madison, WI, USA
  • cDNA encoding the amino terminus of Cyn d I was amplified from the linkered cDNA (5 ⁇ l from a 20 ⁇ l reaction) with 1 ⁇ g each of oligonucleotides AP, 5'- GGGTCTAGAGGTACCGTCCG-3', and CD-5, 5'-GATGTGCTCGTAGTTCTT- 3', an oligonucleotide primer based on non-coding strand sequence of Cyn d I corresponding to the amino acid sequence KNYEHI.
  • the primary polymerase chain reactions (PCR) were carried out in a programmable thermal controller from MJ Research, Inc.
  • Amplified DNA was recovered by sequential chloroform, phenol, and chloroform extractions, followed by precipitation at -20 °C with 0.5 volumes of 7.5 ammonium acetate and 1.5 volumes of isopropanol. After precipitation and washing with 70% ethanol, the DNA was simultaneously digested with Xba I and Bam HI in a 15 pi reaction and electrophoresed through a preparative 3% SeaPlaque low melt agarose gel (FMC Corp., Rockland ME, USA). The appropriate sized DNA band was visualized by ethidium bromide (EtBr) staining, excised, and ligated into appropriately digested M13mpl9 for dideoxy DNA sequencing (Sanger et al, (1977), Proc.
  • EtBr ethidium bromide
  • nucleotides 27-29 contains two potential in-frame methionines, the methionine encoded by nucleotides 27-29 is most probably the initiator methionine since the surrounding sequence more closely matches the consensus plant sequence, 5'-AACAAIG_GC-3' (Lutcke at aL supra), than does the methionine encoded by nucleotides 42-45 (78% vs. 56% match). Furthermore, the sequence surrounding nucleotides 27-29 is identical to that of
  • Cyn d I protein The potential full-length amino acid sequence of Cyn d I designated Cyn rf l.18 (Fig. 9) was created by attaching the sequence of Cyn d l.lA to clone 18 at their overlap as shown in Fig. 9. In both cases, the mature form of Cyn dl is predicted to be 246 amino acids with a calculated molecular weight of 26.7 kDa.
  • the pollen solution was then shaken with phenol (10 ml) for 10 min, after which 10 ml of chlorofornr.isoamyl alcohol 24:1 was added and the mixture shaken for a further 20 min. The mixture was centrifuged at 7,000xg for 25 min and the aqueous phase collected.
  • RNA was isolated using a Pharmacia mRNA Purification kit (Pharmacia, Piscataway, NJ.), following the manufacturers instructions.
  • First strand cDNA was prepared by heating 0.8 ⁇ g mRNA to 70°C with 0.5 ⁇ g of oligo-dT primer (Pharmacia, Piscataway, NJ). After the mRNA solution was cooled on ice, 5X first strand buffer and 25U RNAsin ribonuclease inhibitor were added. The mixture was then heated at 42°C for 1 hr. Final reaction conditions were 50 mM Tris-HCl, pH 8.3, 50 mM KCl, 10 mM MgCl2,
  • RNAsin ribonuclease inhibitor 15u AMV reverse transcriptase/ ⁇ g RNA (Promega cDNA synthesis kit, Proraega, Madison, WI) in a final volume of 25 ⁇ l.
  • cDNA sequences encoding Cyn d I were amplified using the Perkin-Elmer Cet ⁇ s gene amplification kit (U.S. Biochemicals, Cleveland, OH).
  • Nucleotides 1-8 of CDI3'B18 were added to create a Pst I endonuclease restriction site for cloning purposes, while nucleotides 9-26 correspond to non-coding strand sequence complementary to nucleotides 604 to 621 of clone 18 ( Figure 2).
  • the PCR was performed in a Perkin-Elmer Cetus Thermal Cycler (Perkin-Elmer, Norwalk, CT) and consisted of 5 cycles of denaturation (94°C, 1 min), annealing (45°C, 1.5 min), and elongation (72°C, 3 min) followed by 20 cycles of denaturation (94°C, 1 min), annealing (55°C, 1.5 min), and elongation (72°C, 3 min). The final elongation reaction was performed at 72°C for 10 min. Amplified product was recovered by phenol extraction, chloroform extraction, and then precipitation at -20°C with 0.5 vol 7.5 M ammonium acetate and 1.5 volumes isopropanol.
  • Double stranded cDNA was prepared and amplified using oligonucleotide primers CD- 13 and CD- 15 in a primary PCR reaction as described in Example 2.
  • CD-13 has the sequence 5'-TTTCTAGAGCCATCGGCGACAAGCCAGGG- CCC-3', whereas nucletoide 14 could be C or G.
  • Nucleotides 1 through 8 of CD- 13 (5'-TTTCTAGA-3') were added to create a Xba I restriction site for cloning purposes. The remaining nucleotides encoded amino acids
  • CD-15 has the sequence5'-GCGTACTTCACGAGCAGCGCCAG-GTAATT-3',whichcorresponds to non-coding strand sequence complementary to coding strand sequence that encodes amino acids AsnTyrLeuAlaLeuLeuValLysTyrAla (numbered amino acids 159 through 168 of clone 2 (C2) and clone 3 (C3) in Fig. 5).
  • CD-16 has the sequence 5'-TTGAATTCGACACGGCGGAACTGCAGCAT-3', where nucleotide 12 could be G or A.
  • Nucleotides 1 through 8 of CD-16 were added to create an Eco RI restriction site for cloning purposes.
  • Nucleotides 9 through 29 corresponded to non-coding strand sequence complementary to coding strand sequence that encode amino acids MetLeuGlnPheArgArgVal (numbered amino acids 132 through 138 of C2 and C3 i Fig. 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des séquences d'acide nucléique codant le Cyn d'I (élément du groupe I de la famille des allergènes), ou au moins un fragment de celui-ci ou l'équivalent fonctionnel de telles séquences d'acide nucléique. La présente invention concerne également des vecteurs d'expression comprenant de telles séquences d'acide nucléique et les cellules hôtes transformées avec elles. La présente invention concerne de plus l'allergène isolé Cyn d'I protéique du pollen du cynodon ou les fragments de celui-ci. Les allergènes isolés protéiques du pollen du cynodon ou leurs fragments antigéniques ou allergéniques sont utiles pour le diagnostic et le traitement chez un patient de la sensibilité aux allergènes du pollen du cynodon.
PCT/AU1992/000615 1991-11-15 1992-11-13 Allergenes proteiques de l'espece cynodon dactylon WO1993010236A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP92923433A EP0668915A1 (fr) 1991-11-15 1992-11-13 Allergenes proteiques de l'espece cynodon dactylon
JP50882993A JP3618342B2 (ja) 1991-11-15 1992-11-13 シノドン・ダクチロン（Ｃｙｎｏｄｏｎ ｄａｃｔｙｌｏｎ）種のタンパク質のアレルゲン

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPK9529 1991-11-15
AUPK952991 1991-11-15
US07/969,875 US6441157B1 (en) 1991-11-15 1992-10-30 Nucleic acid sequences encoding protein allergens of the species Cynodon dactylon
US07/969,875 1992-10-30

Publications (1)

Publication Number Publication Date
WO1993010236A1 true WO1993010236A1 (fr) 1993-05-27

Family

ID=25644158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1992/000615 WO1993010236A1 (fr) 1991-11-15 1992-11-13 Allergenes proteiques de l'espece cynodon dactylon

Country Status (5)

Country Link
EP (1) EP0668915A1 (fr)
JP (1) JP3618342B2 (fr)
AU (1) AU2926492A (fr)
CA (1) CA2123210A1 (fr)
WO (1) WO1993010236A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017208A1 (fr) * 1993-12-22 1995-06-29 Tvw Telethon Institute For Child Health Research Prophylaxie d'allergie
WO2003024998A1 (fr) * 2001-09-18 2003-03-27 Monash University Epitopes de lymphocytes t de l'allergene cyn d1 provenant de pollen de cynodon
US8753644B2 (en) 2009-02-05 2014-06-17 Circassia Limited Grass peptides for vaccine
CN110373418A (zh) * 2018-01-24 2019-10-25 深圳市作物分子设计育种研究院 调控植物种子大小的基因及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1566292A (en) * 1991-03-14 1992-10-21 University Of Melbourne, The Protein allergens of the species cynodon dactylon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340729C (fr) * 1988-03-23 1999-09-07 Mohan Bir Singh Allergene provenant du pollen de ray-grass
JP3220451B2 (ja) * 1989-03-17 2001-10-22 イミユロジク・フアーマシユーチカル・コーポレーシヨン ブタクサからのアレルゲン蛋白質およびそれらの使用
WO1992016554A1 (fr) * 1991-03-14 1992-10-01 The University Of Melbourne Allergenes proteiques de l'espece cynodon dactylon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1566292A (en) * 1991-03-14 1992-10-21 University Of Melbourne, The Protein allergens of the species cynodon dactylon

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Allergy, Vol. 46 (1991), Z.N. CHANG et al.: "Analysis of Allergenic Components of Bermuda Grass Pollen by Monoclonal Antibodies", see pages 520-528. *
Clinical Allergy, Vol. 18 (1988), S.R. HORNG - DER SHEN et al.: "Identification of Allergens and Antigens of Bermuda Grass (Cynodon Dactylon) Pollen by Immunblot of Analysis", see pages 401-409. *
Electrophoresis, Vol. 8(9), (1987), E. TOVEY et al.: "Characterization of Allergens by Protein Blotting", see pages 452-463. *
S.A. Medical Journal, Vol. 51 (1977), A. ORREN / L. DOWDLE: "Studies on Bermuda Grass Pollen Allergens", see pages 586-591. *
See also references of EP0668915A4 *
The Journal of Allergy & Clinical Immunology: Official Organ of American Academy of Allergy, Vol. 81 (1988), F. MATTHIESEN et al., "Characterization of the Major Allergen of Cynodon Dactylon (Bermuda Grass) Pollen", page 266, Abstract No. 393. *
The Journal of Allergy & Clinical Immunology: Official Organ of American Academy of Allergy; Vol. 79, No. 5 (1987), "Identification of Bermuda Grass (Cynodon Dactylon) - Pollen Allergens by Electroblotting", see pages 711-720. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017208A1 (fr) * 1993-12-22 1995-06-29 Tvw Telethon Institute For Child Health Research Prophylaxie d'allergie
US6333038B1 (en) 1993-12-22 2001-12-25 Tvw Telethon Institute For Child Health Research Princess Margaret Hospital For Children Prophylaxis of allergic disease
WO2003024998A1 (fr) * 2001-09-18 2003-03-27 Monash University Epitopes de lymphocytes t de l'allergene cyn d1 provenant de pollen de cynodon
US9120865B2 (en) * 2001-09-18 2015-09-01 Circassia Limited T cell epitopes of the Cyn d 1 allergen from bermuda grass pollen
US8753644B2 (en) 2009-02-05 2014-06-17 Circassia Limited Grass peptides for vaccine
CN110373418A (zh) * 2018-01-24 2019-10-25 深圳市作物分子设计育种研究院 调控植物种子大小的基因及其应用
CN110373418B (zh) * 2018-01-24 2024-05-10 深圳市作物分子设计育种研究院 调控植物种子大小的基因及其应用

Also Published As

Publication number Publication date
AU2926492A (en) 1993-06-15
JP3618342B2 (ja) 2005-02-09
JPH07502648A (ja) 1995-03-23
EP0668915A4 (fr) 1995-02-24
CA2123210A1 (fr) 1993-05-27
EP0668915A1 (fr) 1995-08-30

Similar Documents

Publication Publication Date Title
JP2007151555A (ja) ハウスダストダニからのアレルゲン蛋白質、ペプチド及びそのための使用
JP3575802B2 (ja) 日本杉花粉からのアレルゲン性蛋白質及びペプチド
WO1994001560A1 (fr) Proteines et peptides allergenes tires du pollen du cedre du japon
US5710126A (en) T cell epitopes of ryegrass pollen allergen
AU6517594A (en) T cell epitopes of ryegrass pollen allergen
EP0665888B2 (fr) Allergene du pollen d'ivraie vivace
AU659609B2 (en) Birch pollen allergen P14 for diagnosis and therapy of allergic diseases
US6982326B1 (en) Allergenic proteins and peptides from Japanese cedar pollen
EP0495052A1 (fr) Allergenes du pollen de l'aulne et leurs applications
US6214358B1 (en) Protein allergens of the species Cynodon dactylon
JP4102432B2 (ja) 杉花粉由来のアレルゲン性蛋白質及びペプチド
US7514083B1 (en) Protein allergens of the species cynodon dactylon
WO1992016554A1 (fr) Allergenes proteiques de l'espece cynodon dactylon
US6335020B1 (en) Allergenic peptides from ragweed pollen
EP0668915A1 (fr) Allergenes proteiques de l'espece cynodon dactylon
US7485305B2 (en) Allergen from house-dust mites
US6090386A (en) T cell peptides of the CRX JII allergen
AU709537B2 (en) Protein allergens of the species Cynodon dactylon
US20030180225A1 (en) Walnut and ryegrass allergens
AU3438493A (en) Allergenic proteins and peptides from japanese cedar pollen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2123210

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992923433

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992923433

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992923433

Country of ref document: EP